CD274 and neoplasm: Many factors can affect the effectiveness of immune checkpoint inhibitor therapy, including tumour mutation burden (TMB), programmed cell death-ligand 1 (PD-L1) expression, T-cell infiltration, and human leucocyte antigen (HLA) diversity16.